All In Biotech

NDA 213581 · Bausch and Lomb INC

Atropine Sulfate

Atropine Sulfate · Ophthalmic

Last checked: Nov 19, 2026Latest source record: Mar 15, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Mar 15, 2022

Approved uses

1

Original approval plus efficacy supplements

Registered trials

414

74 Phase 3, 30 recruiting

FAERS reports

2,540

2,136 serious, 398 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Feb 7, 2026.

Atropine Sulfate Ophthalmic Solution, USP 1% is indicated for: Atropine is an anti-muscarinic agent indicated for: Mydriasis ( 1.1 ) Cycloplegia ( 1.2 ) Penalization of the healthy eye in the treatment of amblyopia ( 1.3 ) 1.1 Mydriasis 1.2 Cycloplegia 1.3 Penalization of the Healthy Eye in the Treatment of Amblyopia

Mechanism: Atropine is a reversible antagonist of muscarine-like actions of acetylcholine and is therefore classified as an anti-muscarinic agent. Atropine is relatively selective for muscarinic receptors. Its potency at nicotinic receptors is much lower, and actions at non-muscarinic receptors are generally undetectable clinically. Atropine does not distinguish among the M1, M2, and M3 subgroups of muscarinic receptors. The pupillary constrictor muscle depends on muscarinic cholinoceptor activation. This activation is blocked by topical atropine resulting in unopposed sympathetic dilator activity and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 15, 2022 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
1 products under this application
  • ATROPINE SULFATE · ATROPINE SULFATE 1% · SOLUTION/DROPS, OPHTHALMIC · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Atropine" as an intervention, any sponsor and status, largest first.

All 414 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective315
  • off label use211
  • macular degeneration199
  • nausea193
  • pyrexia161
  • diarrhoea149
  • pain136
  • malaise132
  • headache129
  • weight decreased120
  • death118
  • constipation115

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200455
200562
200650
200755
200872
200945
201075
201167
201271
201360
201467
201574
2016112
201790
2018122
2019181
2020158
2021146
2022226
2023231
2024232
2025185
2026103

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Atropine Sulfate (Atropine Sulfate/PF)

2024 spending

$26K

Beneficiaries

389

541 claims

Per beneficiary

$66

$4.08 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$16,880
2024$25,522

Part D: Atropine Sulfate* (Atropine Sulfate)

2024 spending

$8.9M

Beneficiaries

122,395

214,955 claims

Per beneficiary

$73

$7.76 per unit

View as table
YearSpending
2020$1,723
2021$92,485
2022$5,163,655
2023$8,217,428
2024$8,948,517

Part B: Atropine Sulfate* (Atropine Sulfate*) · HCPCS J0461

2024 spending

$184K

Beneficiaries

9,157

50,874 claims

Per beneficiary

$20

2024 ASP limit $0.09 per unit

View as table
YearSpending
2020$168,296
2021$197,768
2022$182,791
2023$189,665
2024$184,194

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,885 on PubMed

Sponsor: Bausch and Lomb INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.